Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2023)

Revolution Medicines' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 37.5% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $8.0 million (up 29.03% YoY), while the FY2025 annual figure was $7.4 million, up 19.35% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.2 million in Q1 2026, with the low at $901000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.4 million (2024), against an average of $1.5 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 50.0% in 2025, while the deepest fall reached 6.25% in 2025.
• Revolution Medicines' Depreciation & Amortization (CF) stood at $1.2 million in 2022, then climbed by 10.88% to $1.3 million in 2023, then increased by 7.28% to $1.4 million in 2024, then jumped by 50.0% to $2.1 million in 2025, then rose by 4.76% to $2.2 million in 2026.
• Business Quant data shows RVMD's Depreciation & Amortization (CF) at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.